Second Quarter 2025 Financial Report and Disclosures

This financial document from Gilead Sciences, Inc. provides a comprehensive overview of the company's financial performance and position for the three and six months ended June 30, 2025, with comparative data for 2024. It details balance sheet figures, including assets, liabilities, and stockholders' equity, alongside income statement components like revenues, expenses, and net income, highlighting key changes and contributing factors. The report also addresses cash flow activities, fair value measurements of financial instruments, and significant intangible assets, noting impairment charges related to certain research and development projects. Furthermore, it outlines critical accounting estimates, ongoing legal proceedings with generic manufacturers, and various risk factors that could impact the business, such as competition, regulatory changes, supply chain challenges, and intellectual property protection. Finally, the document includes details on equity incentive plans for employees and non-employee directors, explaining the terms for stock options and restricted stock units.

There are no comments yet.

Please log in to write the first comment.